|Traded as||NASDAQ: GTXI|
|Founded||September 24, 1997|
|Headquarters||Memphis, Tennessee, United States|
|Products||Toremifene, Ostarine, Andarine|
GTx, Inc is a pharmaceutical company and developer of drugs that utilize hormonal pathways. Its major product to date is toremifene, and drugs in development include enobosarm (ostarine) and GTx-758. The company has undertaken partnerships with other biotechnology companies such as Merck in the development of drugs in the selective estrogen receptor modulator (SERM) and selective androgen receptor modulator (SARM) classes.
- "About GTx". Retrieved May 17, 2011.
- "GTx Presents Phase II Ostarine (MK-2866) Cancer Cachexia Clinical Trial Results at Endocrine Society Annual Meeting". Retrieved May 17, 2011.
|This biotechnology article is a stub. You can help Wikipedia by expanding it.|
|This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.|